

ROS Therapeutics welcomes Henrik Fenger as a member of the Board of Directors.

June 01, 2022

ROS Therapeutics proudly welcomes Henrik Fenger as a member of the company's Board of Directors. Henrik comes with a long history and knowledge in marketing and sales of methotrexate gained from various director positions at Medac GmbH in Germany and the US. Henrik has also previously served as General Manager of Scandinavia for Medac GmbH, the market leader of methotrexate in Europe.

"I am very pleased that Henrik has joined our Board of Directors. Henrik comes with an excellent background that fits well to our needs for competences and complements the skills of our Board of Directors. His hands-on experience in marketing and sales, and particularly his strong focus on methotrexate, coupled with his extensive network in this field, makes him a perfect match" says Hanne Damgaard Jensen.

"I am looking very much forward to bringing my expertise and network into play at ROS Therapeutics. There is a need for better methotrexate products, and I am comfortable and hopeful that Trexior may address some of the shortcomings of existing methotrexate products. I am looking forward to help advancing a potentially better treatment", says Henrik Fenger.

About Trexior™: Trexior is an innovative proprietary and potentially best-in-class orally delivered methotrexate therapy. Several of the shortcomings of existing methotrexate therapies, whether oral or injections, are sought overcome with Trexior.

About methotrexate: Methotrexate is a cornerstone treatment for JIA, one of the most common childhood diseases, as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults. Since the early 90'ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies.

About ROS Therapeutics: ROS Therapeutics ApS is a development stage pharmaceutical company, committed to optimize the treatment experience with methotrexate and address unmet needs of children with JIA and other autoimmune and chronic inflammatory conditions.

For further information please contact:

Hanne Damgaard Jensen, CEO ROS Therapeutics; hdj@rosterapeutics.com; Tel: +45 4078 6888